ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · J Infect Dis · 2026-09-23

Secondary analysis of female students aged 18-24 in the i-Predict trial (24 with incident infection vs 260 uninfected): CST IV vaginal microbiota (OR 3.77) and multiple concurrent partners (OR 5.40) were associated with C. trachomatis acquisition; condom use with lower risk.

Secondary analysisn = 313
Tamarelle et al. Chlamydia trachomatis Incidence in Relation to Vaginal Microbiota Dynamics, Immunogenetics and Exposures in a Cohort of Young Student Women in France
Infectious diseases · Vaccine · 2026-09-17

Secondary analysis of the PrevHPV trial (2758 French adolescents aged 13–15, 39 schools): school educational activities raised HPV vaccine uptake or intention (OR 1.57), mediated mainly by better attitudes on benefit-risk, safety and access, not knowledge alone.

Secondary analysisn = 2,758
Munoz et al. Which changes in adolescents' knowledge, attitudes, and practices following a school-based intervention in France increase HPV vaccination uptake and intentions? A mediation analysis
Infectious diseases · Clin Infect Dis · 2026-07-23

Phase 1b/2 trial in women with persistent high-risk HPV and low-grade cervical lesions: VTP-200 was well tolerated and immunogenic, but secondary-outcome HPV clearance did not differ from placebo (31.3% vs 33.3%), nor did lesion clearance.

RCTn = 108
Hellner et al. A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions
Infectious diseases · Vaccine · 2026-07-08

In 670 healthy 15–25-year-olds, the quadrivalent HPV vaccine Papilloguard (with AS04 adjuvant) was non-inferior to Gardasil for antibody responses to HPV 6, 11, 16 and 18 at day 210. Higher responses were not prespecified, and local reactions were more frequent.

RCTn = 670
Mardani et al. Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial
Infectious diseases · Int J Infect Dis · 2026-06-30

Systematic review and meta-analysis of 85 studies (31 countries): pooled STI prevalence in international migrants was 53.55/1000 for chlamydia, 20.77 for gonorrhoea and 17.36 for probable active syphilis; migrants had higher syphilis but not gonorrhoea prevalence ratios.

Meta-analysisn = 85 studies
Mackey et al. Estimates of sexually transmitted infection prevalence and prevalence ratio among international migrants compared with non-migrants: A global systematic review and meta-analysis
Infectious diseases · Lancet Infect Dis · 2026-06-30

In 399 MSM at Chinese community organisations, doxy-PEP use after condomless sex at 6 months was 41% with co-created education alone vs 76% when free pay-it-forward doxy-PEP was added and 73% with added social network distribution (both p<0·0001).

RCTn = 399
Fitzpatrick et al. Community-engaged implementation strategies to increase doxycycline post-exposure prophylaxis uptake among men who have sex with men in China (DoxyForward): a three-group, open-label, randomised controlled trial
Infectious diseases · Lancet Infect Dis · 2026-06-30

In 9327 Chinese women aged 18–45, an E coli-produced nine-valent HPV vaccine was non-inferior to the bivalent vaccine for HPV 16/18 antibodies and showed 98·2% efficacy against 12-month persistent HPV 31/33/45/52/58 infection; adverse reactions 52·1% vs 42·2%.

RCTn = 9,327
Pan et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial
Infectious diseases · Vaccine · 2026-04-02

Phase 2 trial in 1800 females aged 9-45 (vaccine vs placebo, 2:1): the quadrivalent HPV 6/11/16/18 vaccine gave seroconversion of 99.7-100% in seronegative participants, and 9-17-year-olds were non-inferior to 18-45-year-olds; no vaccine-related serious events.

RCTn = 1,800
Yang et al. Immunogenicity and safety of a quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha): A randomized controlled phase 2 non-inferiority clinical trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.